This study aims at evaluate the effect of adalimumab with patient support program (PSP) on clinical, health economic, patient reported outcomes in patients with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, Crohn's disease and ulcerative colitis in the routine clinical setting in Hungary.